Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Multiple Myeloma 4Lymphoma 3Glioblastoma 3Recurrence 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell, Marginal Zone 2Glioma 2Brain Neoplasms 2Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Melanoma 1Leukemia 1Gliosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 94Radiotherapy 59Bevacizumab 59Radiosurgery 41Carboplatin 27Irinotecan 26Magnetic Resonance Spectroscopy 25Surgical Procedures, Operative 23Etoposide 22Carmustine 20Filgrastim 18Erlotinib Hydrochloride 17Cyclophosphamide 16Cisplatin 16Vincristine 15Lomustine 15Lapatinib 15Sorafenib 13Radiation 13Trastuzumab 12Nivolumab 12Imatinib Mesylate 12Thalidomide 11Surveys and Questionnaires 11Granulocyte Colony-Stimulating Factor 11Radiotherapy, Intensity-Modulated 10Aminolevulinic Acid 10temsirolimus 9Topotecan 9Thiotepa 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Brain Neoplasms × marizomib × Clear all
NCT02330562 2022-06-08

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

Celgene

Phase 1/2 Completed
121 enrolled 27 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT02903069 2021-04-19

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

Celgene

Phase 1 Completed
66 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡